Salivary gland tumor classification encompasses a vast list of benign and malignant neoplasms. Their morphological diversity is recognized not only between different entities but also within individual tumors. Tumor categories as described by the World Health Organization reflect, in part, a true genetic heterogeneity (e.g., translocations involving CRTC1 and CRTC3-MAML2 genes in mucoepidermoid carcinoma and MYB-NFIB fusion in adenoid cystic carcinoma). Carcinoma ex pleomorphic adenoma shows diversity in its histological appearance, but recurrent rearrangements on PLAG1 and HMGA2 are common to its benign precursor. More recently, new categories have been defined, like secretory carcinoma with the t(12;15) (p13;q25) ETV6-NTRK3 translocation and clear-cell carcinoma with EWSR1-ATF1 fusion. Recent studies on cribriform adenocarcinoma of minor salivary gland origin and epithelial-myoepithelial carcinoma point to a correlation with their morphological features. All of these advances show that the search of a histogenetic and genetic basis for salivary gland tumors is helping to clarify morphological categories and unraveling new ones. Nevertheless, currently morphology is still the hallmark of tumor classification and the gold standard. The therapeutic options for advanced tumors remain very limited but the discovery of translocation-generated gene fusions and increased knowledge of the genomic information of salivary gland tumors is creating opportunities for the development of specific targeted therapies.

1.
WHO Classification of Head and Neck Tumours, ed 4. Lyon, WHO, 2017.
2.
Wenig BM: Atlas of Head and Neck Pathology, ed 3. Amsterdam, Elsevier, 2015.
3.
Spiro RH, Huvos AG, Strong EW: Acinic cell carcinoma of salivary origin: a clinicopathologic study of 67 cases. Cancer 1978;41:924-935.
4.
Batsakis JG, Kraemer B, Sciubba JJ: The pathology of head and neck tumors: the myoepithelial cell and its participation in salivary gland neoplasia. Part 17. Head Neck Surg 1983;5:222-233.
5.
Savera AT, Sloman A, Huvos AG, Klimstra DS: Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol 2000;24:761-774.
6.
Cibas ES, Ducatman BS: Cytology: Diagnostic Principles and Clinical Correlates, ed 4. Philadelphia, Saunders, 2014.
7.
Wilson TC, Robinson RA: Basal cell adenocarcinoma and basal cell adenoma of the salivary glands: a clinicopathological review of seventy tumors with comparison of morphologic features and growth control indices. Head Neck Pathol 2015;9:205-213.
8.
Seethala RR: An update on grading of salivary gland carcinomas. Head Neck Pathol 2009;3:69-77.
9.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
10.
AJCC Cancer Staging Manual, ed 8. Chicago, Springer, 2017.
11.
Rito M, Fonseca I: Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma. Virchows Arch 2016;468:297-303.
12.
Lewis JE, Olsen KD, Sebo TJ: Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 2001;32:596-604.
13.
Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R: Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol 2010;41:927-934.
14.
Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, Kirchner T, Ihrler S: Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 2011;59:741-750.
15.
Nagao T: “Dedifferentiation” and high-grade transformation in salivary gland carcinomas. Head Neck Pathol 2013;7(suppl 1):S37-S47.
16.
Foote FW Jr, Frazell EL: Tumors of the Major Salivary Glands. Washington, Armed Forces Institute of Pathology, 1954.
17.
Jungehulsing M, Wagner M, Damm M: Turban tumour with involvement of the parotid gland. J Laryngol Otol 1999;113:779-783.
18.
Reingold IM, Keasbey LE, Graham JH: Multicentric dermal-type cylindromas of the parotid glands in a patient with florid turban tumor. Cancer 1977;40:1702-1710.
19.
Choi HR, Batsakis JG, Callender DL, Prieto VG, Luna MA, El-Naggar AK: Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma? Am J Surg Pathol 2002;26:778-783.
20.
Malzone MG, Campanile AC, Losito NS, Longo F, Perri F, Caponigro F, Schiavone C, Ionna F, Maiello F, Martinuzzi C, Nasti S, Botti G, Fulciniti F: Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene. Diagn Cytopathol 2015;43:654-658.
21.
Depowski PL, Setzen G, Chui A, Koltai PJ, Dollar J, Ross JS: Familial occurrence of acinic cell carcinoma of the parotid gland. Arch Pathol Lab Med 1999;123:1118-1120.
22.
Albeck H, Bentzen J, Ockelmann HH, Nielsen NH, Bretlau P, Hansen HS: Familial clusters of nasopharyngeal carcinoma and salivary gland carcinomas in Greenland natives. Cancer 1993;72:196-200.
23.
Ahn MS, Hayashi GM, Hilsinger RL Jr, Lalwani AK: Familial mixed tumors of the parotid gland. Head Neck 1999;21:772-775.
24.
Yoshioka N, Mese H, Okui T, Ibaragi S, Sasaki A: Familial adenoid cystic carcinoma of sublingual salivary glands. J Oral Maxillofac Surg Med Pathol 2015;27:353-356.
25.
Gallego L, Junquera L, Villarreal P, Villalain L: Familial Warthin tumor: occurrence in monozygotic twins. J Oral Maxillofac Surg 2010;68:1400-1401.
26.
Aro K, Klockars T, Leivo I, Makitie A: Familial predisposition for salivary gland cancer in Finland. Clin Med Insights Ear Nose Throat 2014;7:7-11.
27.
Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010;34:599-608.
28.
Chiosea SI, Griffith C, Assaad A, Seethala RR: The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. Am J Surg Pathol 2012;36:343-350.
29.
Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH: Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. Am J Surg Pathol 2013;37:1053-1057.
30.
El-Naggar AK, Abdul-Karim FW, Hurr K, Callender D, Luna MA, Batsakis JG: Genetic alterations in acinic cell carcinoma of the parotid gland determined by microsatellite analysis. Cancer Genet Cytogenet 1998;102:19-24.
31.
Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C: Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res 2010;70:9143-9152.
32.
Ito Y, Ishibashi K, Masaki A, Fujii K, Fujiyoshi Y, Hattori H, Kawakita D, Matsumoto M, Miyabe S, Shimozato K, Nagao T, Inagaki H: Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol 2015;39:602-610.
33.
Skalova A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, Steiner P, Michal M: Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol 2016;40:3-13.
34.
Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M: Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol 2015;46:94-103.
35.
Zhu S, Schuerch C, Hunt J: Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med 2015;139:55-66.
36.
Weinreb I: Hyalinizing clear cell carcinoma of salivary gland: a review and update. Head Neck Pathol 2013;7(suppl 1):S20-S29.
37.
World Health Organization: Pathology and Genetics of Head and Neck Tumours. Lyon, IARC Press, 2005.
38.
Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, Jordan RC, Perez-Ordonez B, Have C, Asa SL, Leong IT, Bradley G, Klieb H, Weinreb I: EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer 2011;50:559-570.
39.
Bilodeau EA, Weinreb I, Antonescu CR, Zhang L, Dacic S, Muller S, Barker B, Seethala RR: Clear cell odontogenic carcinomas show EWSR1 rearrangements: a novel finding and a biological link to salivary clear cell carcinomas. Am J Surg Pathol 2013;37:1001-1005.
40.
Yin LX, Ha PK: Genetic alterations in salivary gland cancers. Cancer 2016;122:1822-1831.
41.
Anzick SL, Chen WD, Park Y, Meltzer P, Bell D, El-Naggar AK, Kaye FJ: Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer 2010;49:59-69.
42.
Nakayama T, Miyabe S, Okabe M, Sakuma H, Ijichi K, Hasegawa Y, Nagatsuka H, Shimozato K, Inagaki H: Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 2009;22:1575-1581.
43.
Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I: A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands. J Mol Diagn 2004;6:205-210.
44.
Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, Shimozato K, Eimoto T, Nakamura S, Nagai N, Hasegawa Y, Inagaki H: MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 2006;12:3902-3907.
45.
Fehr A, Roser K, Belge G, Loning T, Bullerdiek J: A closer look at Warthin tumors and the t(11;19). Cancer Genet Cytogenet 2008;180:135-139.
46.
Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK: CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer 2007;46:708-715.
47.
Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, Weber RS, Caulin C, El-Naggar AK: Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010;16:4722-4731.
48.
West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, Kwok S, Montgomery KD, Varma S, Le QT: MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011;35:92-99.
49.
Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G: Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009;106:18740-18744.
50.
Di Palma S, Fehr A, Danford M, Smith C, Stenman G: Primary sinonasal adenoid cystic carcinoma presenting with skin metastases - genomic profile and expression of the MYB-NFIB fusion biomarker. Histopathology 2014;64:453-455.
51.
Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, El-Naggar AK: Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res 2016;22:725-733.
52.
Brayer KJ, Frerich CA, Kang H, Ness SA: Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic rathway in salivary gland adenoid cystic carcinoma. Cancer Discov 2016;6:176-187.
53.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV: Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 2017;35:352-360.
54.
Simpson RH, Skalova A, Di Palma S, Leivo I: Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch 2014;465:371-384.
55.
Andersson MK, Stenman G: The landscape of gene fusions and somatic mutations in salivary gland neoplasms - implications for diagnosis and therapy. Oral Oncol 2016;57:63-69.
56.
Mariano FV, Noronha AL, Gondak RO, Altemani AM, de Almeida OP, Kowalski LP: Carcinoma ex pleomorphic adenoma in a Brazilian population: clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg 2013;42:685-692.
57.
Zbaren P, Zbaren S, Caversaccio MD, Stauffer E: Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome. Otolaryngol Head Neck Surg 2008;138:601-605.
58.
Antony J, Gopalan V, Smith RA, Lam AK: Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 2012;6:1-9.
59.
Stenman G: Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 2013;7(suppl 1): S12-S19.
60.
Antonescu CR, Zhang L, Shao SY, Mosquera JM, Weinreb I, Katabi N, Fletcher CD: Frequent PLAG1 gene rearrangements in skin and soft tissue myoepithelioma with ductal differentiation. Genes Chromosomes Cancer 2013;52:675-682.
61.
Bahrami A, Dalton JD, Krane JF, Fletcher CD: A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosomes Cancer 2012;51:140-148.
62.
Declercq J, Van Dyck F, Braem CV, Van Valckenborgh IC, Voz M, Wassef M, Schoonjans L, Van Damme B, Fiette L, Van de Ven WJ: Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res 2005;65:4544-4553.
63.
Persson F, Andren Y, Winnes M, Wedell B, Nordkvist A, Gudnadottir G, Dahlenfors R, Sjogren H, Mark J, Stenman G: High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer 2009;48:69-82.
64.
Katabi N, Ghossein R, Ho A, Dogan S, Zhang L, Sung YS, Antonescu CR: Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol 2015;46:26-33.
65.
Head and neck pathology. Mod Pathol 2017;30:319-335.
66.
Martins C, Fonseca I, Roque L, Pereira T, Ribeiro C, Bullerdiek J, Soares J: PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma: a combined study using chromosome banding, in situ hybridization and immunocytochemistry. Mod Pathol 2005;18:1048-1055.
67.
Debiec-Rychter M, Van Valckenborgh I, Van den Broeck C, Hagemeijer A, Van de Ven WJ, Kas K, Van Damme B, Voz ML: Histologic localization of PLAG1 (pleomorphic adenoma gene 1) in pleomorphic adenoma of the salivary gland: cytogenetic evidence of common origin of phenotypically diverse cells. Lab Invest 2001;81:1289-1297.
68.
Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Nishiyama K, Higaki Y, Komune S, Tsuneyoshi M, Oda Y: HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study. Histopathology 2012;60:E131-E142.
69.
Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham D, Washburn D, Wong S, Chmiekecki J, Yelensky R, Lipson D, Miller V, Serracino HS, Stephens PJ, Ross JS, Bowles DW: Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 2016;22:6061-6068.
70.
von Holstein SL, Fehr A, Persson M, Nickelsen M, Therkildsen MH, Prause JU, Heegaard S, Stenman G: Lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma: genomic profiles, gene fusions, and clinical characteristics. Ophthalmology 2014;121:1125-1133.
71.
Mariano FV, Giovanetti K, Saccomani LF, Del Negro A, Kowalski LP, Krepischi AC, Altemani A: Carcinoma ex-pleomorphic adenoma derived from recurrent pleomorphic adenoma shows important difference by array CGH compared to recurrent pleomorphic adenoma without malignant transformation. Braz J Otorhinolaryngol 2016;82:687-694.
72.
Roijer E, Nordkvist A, Strom AK, Ryd W, Behrendt M, Bullerdiek J, Mark J, Stenman G: Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 2002;160:433-440.
73.
Yamamoto Y, Kishimoto Y, Virmani AK, Smith A, Vuitch F, Albores-Saavedra J, Gazdar AF: Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol 1996;27:782-786.
74.
Skalova A, Sima R, Kaspirkova-Nemcova J, Simpson RH, Elmberger G, Leivo I, Di Palma S, Jirasek T, Gnepp DR, Weinreb I, Perez- Ordonez B, Mukensnabl P, Rychly B, Hrabal P, Michal M: Cribriform adenocarcinoma of minor salivary gland origin principally affecting the tongue: characterization of new entity. Am J Surg Pathol 2011;35:1168-1176.
75.
Seethala RR, Stenman G: Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol 2017;11:55-67.
76.
Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B, Harding NJ, Alfaro J, Chu KC, Viale A, Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LD, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M, Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu FF, Norton L, McPherson JD, Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS: Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 2014;46:1166-1169.
77.
Weinreb I, Zhang L, Tirunagari LM, Sung YS, Chen CL, Perez-Ordonez B, Clarke BA, Skalova A, Chiosea SI, Seethala RR, Waggott D, Boutros PC, How C, Liu FF, Irish JC, Goldstein DP, Gilbert R, Ud Din N, Assaad A, Hornick JL, Thompson LD, Antonescu CR: Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer 2014;53:845-856.
78.
Chiosea SI, Miller M, Seethala RR: HRAS mutations in epithelial-myoepithelial carcinoma. Head Neck Pathol 2014;8:146-150.
79.
Fonseca I, Bell A, Wani K, Bell D: Global transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimens. Genes Chromosomes Cancer 2015;54:249-259.
80.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Fort Washington, NCCN, 2017.
81.
Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R: Genomic landscape of salivary gland tumors. Oncotarget 2015;6:25631-25645.
82.
Stenman G, Persson F, Andersson MK: Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 2014;50:683-690.
83.
Bell D, Hanna EY: Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep 2012;14:166-174.
84.
Wilson TC, Ma D, Tilak A, Tesdahl B, Robinson RA: Next-generation sequencing in salivary gland basal cell adenocarcinoma and basal cell adenoma. Head Neck Pathol 2016;10:494-500.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.